Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Agenus Inc. - Common Stock (NQ: AGEN )

1.675 -0.005 (-0.30%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Agenus Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Agenus Prioritizes Resources to Accelerate Registration and Commercialization of BOT/BAL Program in Multiple Cancers
From Agenus Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
SaponiQx Announces Breakthrough in Scaling Up of STIMULON™ Cultured Plant Cell Adjuvant
From SaponiQx
Via Business Wire
Agenus Reports Second Quarter 2023 Results
From Agenus Inc.
Via Business Wire
Agenus (AGEN) Q1 2023 Earnings Call Transcript
AGEN earnings call for the period ending March 31, 2023. 
Via The Motley Fool
Agenus' Investigational Cancer Combo Therapy Shows 33% Durable Responses In Ovarian Cancer
Via Benzinga
Agenus Botensilimab/Balstilimab Data Update in Sarcomas Selected for Oral Presentation at ESMO 2023
From Agenus Inc.
Via Business Wire
Agenus to Provide Second Quarter 2023 Financial Report and Corporate Update
From Agenus
Via Business Wire
Agenus Expands Executive Leadership Team
From Agenus Inc.
Via Business Wire
ESMO GI Data: Agenus' Botensilimab/Balstilimab Combination Achieves Unprecedented Survival in Advanced Colorectal Cancer
From Agenus
Via Business Wire
Why Agenus Stock Is Slumping This Week
The biotech may have to raise capital soon. 
Via The Motley Fool
2 Low-Priced Stocks That Could Make You Richer
These two low-priced healthcare stocks could skyrocket within the next 12 months. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For June 6, 2023
Via Benzinga
Agenus Presents Positive Efficacy and Safety Outcomes for AGEN2373 at ASCO
From Agenus Inc.
Via Business Wire
Why Amedisys Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Sono Group N.V. (NYSE: SEV) shares surged 152.7% to $0.4367. Sono Group applied to Insolvency Court of Munich, Germany, to permit opening of self-administration proceeding. 
Via Benzinga
Agenus Announces Virtual Annual Shareholders Meeting
From Agenus
Via Business Wire
Agenus to Participate in Jefferies Healthcare Conference
From Agenus
Via Business Wire
Agenus Provides Corporate Update and First Quarter 2023 Financial Results
From Agenus Inc.
Via Business Wire
Agenus Selected for Late-Breaking Oral Presentation at ESMO-GI
From Agenus
Via Business Wire
Agenus (NASDAQ: AGEN) Featured in Coverage of the Inaugural EF Hutton Global Conference
Via Investor Brand Network
Agenus to Present at the American Society of Clinical Oncology 2023 Annual Meeting
From Agenus
Via Business Wire
Agenus to Provide Corporate Update and First Quarter 2023 Financial Report
From Agenus
Via Business Wire
Agenus to Participate in May Investor Conferences
From Agenus
Via Business Wire
Why Travelers Companies Shares Are Trading Higher By Over 5%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) gained 85.2% to $1.25 after the company announced the termination of its previously proposed registered direct offering. 
Via Benzinga
These 3 Nasdaq Stocks Are on Fire Today: Here's Why
A high-dollar buyout is lighting a fire underneath these three Nasdaq stocks today. 
Via The Motley Fool
Agenus Receives Fast Track Designation for Botensilimab and Balstilimab in Colorectal Cancer
From Agenus Inc.
Via Business Wire
Gain Therapeutics Appoints C. Evan Ballantyne as Chief Financial Officer
From Gain Therapeutics, Inc.
Via GlobeNewswire
Why Agenus, Amarin, and Axsome Therapeutics Shares Slumped Today
Macro headwinds are weighing on risk-laden biotech stocks today. 
Via The Motley Fool
Agenus Announces Dividend of 5 Million Shares of MiNK Therapeutics
From Agenus Inc.
Via Business Wire
Agenus’ Botensilimab in Combination with Balstilimab Shows 33% Durable Responses in Ovarian Cancer
From Agenus Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.